Bmrn analyst rating
WebApr 10, 2024 · Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Quest Diagnostics (DGX) and Globus Medical (GMED) Mar. 17, 2024 at 5:20 … WebMar 7, 2024 · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $122.56 average price target, which is a 29.0% upside from current levels.
Bmrn analyst rating
Did you know?
WebFind the latest BioMarin Pharmaceutical Inc. BMRN analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range investment rating... WebMar 22, 2024 · 1/30/2024 – BioMarin Pharmaceutical is now covered by analysts at BMO Capital Markets. They set a “market perform” rating and a $107.00 price target on the stock. 1/24/2024 – BioMarin ...
WebBMRN Analyst Ratings Moderate Buy 19 Ratings 12 Buy 6 Hold 1 Sell Based on 19 analysts giving stock ratings to BioMarin Pharmaceutical in the past 3 months BMRN … WebFeb 24, 2024 · BMRN BioMarin Pharmaceutical Inc.Wall St. Analysts Ratings & Price Target. $102.07 -1.11 ( -1.08%) 4:00 PM 02/24/23. NASDAQ $USD Market Close. …
WebApr 6, 2024 · Rating: P/E Non-GAAP (FWD) 47.12 P/E GAAP (TTM) 132.80 Price/Book (TTM) 4.03 EV/Sales (TTM) 8.78 EV/EBITDA (TTM) 124.43 More On Valuation » Growth Profitability Rating: Gross Profit Margin... WebApr 9, 2024 · Analyst Ratings Changes Several brokerages have commented on BMRN. Bank of America raised their target price on shares of BioMarin Pharmaceutical to $200.00 in a report on Wednesday, January 4th.
WebMar 21, 2024 · Where Biomarin Pharmaceutical Stands With Analysts - Biomarin Pharmaceutical (NASDAQ:BMRN) - Benzinga Español India Italiano Français My Account My Account Notifications Overview + New...
WebApr 9, 2024 · Xponance Inc. grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Rating) by 81.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.The institutional investor owned 6,503 shares of the biotechnology company's stock after purchasing an additional … beckman's dog training puppyWebBiomarin Pharmaceutical Stock (NASDAQ:BMRN), Analyst Ratings, Price Targets, Predictions Analysts publish ratings and price targets on most stocks. Benzinga tracks … dj brabWebMar 1, 2024 · BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN – Get Rating) shares gapped down before the market opened on Tuesday after Canaccord Genuity Group lowered their price target on the stock from $119.00 ... beckmann bad driburgWebApr 13, 2024 · Strs Ohio cut its stake in BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN - Get Rating) by 44.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,000 shares of the biotechnology company's stock after selling 12,959 shares during the quarter. dj braga cacheWebApr 13, 2024 · According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.15. Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently modified their holdings of BMRN. dj brabant nlWebApr 8, 2024 · In a report released on April 6, Luca Issi from RBC Capital maintained a Hold rating on BioMarin Pharmaceutical ( BMRN – Research Report ), with a price target of $100.00. The company’s shares ... beckman\u0027s dog training redditWebApr 10, 2024 · BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2024 and is poised for U.S. approval in 2024. Contact. 770 Lindaro Street. San Rafael, CA, 94901. www.bmrn.com. dj bracelets